Insights From:Tanios Bekaii-Saab, MD, FACP, Mayo Clinic; Andrea Cercek, MD, Memorial Sloan Kettering Cancer Center; Zev A. Wainberg, MD, David Geffen School of Medicine at UCLA. Despite a very grim prognosis in stage 4 pancreatic cancer, it’s exciting that we’re bringing 2 new modalities onboard in the frontline setting that are standard of care.
We even have a second-line, post-gemcitabine standard-of-care treatment option—nanoliposomal irinotecan. It’s FDA approved for post-gemcitabine advanced pancreatic cancer, metastatic or not, in combination with fluorouracil (5-FU) and leucovorin. Watch here . . .